A Phase 1 interventional study of Olatorepatide in adults living with overweight or obesity without diabetes
Not Yet Recruiting Phase 2 NCT07685808
Study Description
A clinical study testing a new injectable weight loss medication called Olatorepatide to evaluate its safety, tolerability, and effectiveness in adults who are overweight or obese but do not have diabetes
Study Details
- Registry ID:
- NCT07685808
- Conditions:
- Overweight or Obesity
- Phase:
- Phase 2
- Target Enrollment:
- 360 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.